New
AVITA Medical: clinical trials in the USA
First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.
AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.
The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)
For more information, please contact: Elizabeth Kirshner at 661-367-9180 or ekirshner@avitamedical.com
FAQOther Questions
- What causes vitiligo?
The exact cause is a complex puzzle, but we know the foundation: It is pre-wired in your genes. Think of your genetics as a loaded spring, just waiting for a specific "trigger" ...
- Which skin conditions can be mistaken for vitiligo?
Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...
- Is there a special diet for vitiligo?
Recent research highlights the potential of diet and nutrition in managing vitiligo, offering an alternative where traditional therapies may be lacking. However, the relationshi...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.